Merck Aims To Duplicate Januvia Launch Success In 2007
This article was originally published in The Pink Sheet Daily
Executive Summary
Launches for Janumet, Arcoxia and Emend IV are keys to continuing the momentum of firm’s turnaround plan, CEO Clark says.
You may also be interested in...
Merck Gains Positive Opinion For Januvia In EU
Firm expects final EU clearance in early April.
Merck Gains Positive Opinion For Januvia In EU
Firm expects final EU clearance in early April.
Skin Toxicity Seen In Other DPP-4 Inhibitors Missing In Januvia NDA – FDA Review
FDA’s request for additional primate studies to assess potential skin toxicity stemmed from findings with other agents of the same class, agency review documents show.